NCT01872598View on ClinicalTrials.gov

Masitinib in Patients With Mild to Moderate Alzheimer's Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

721

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2020

Conditions
Alzheimer Disease
Interventions
DRUG

Masitinib

DRUG

Placebo

DRUG

Standard of care

stable dose of cholinesterase inhibitor (donepezil, rivastigmine or galantamine) and/or memantine, as per standard practice.

Trial Locations (6)

9010

MHAT Sveta Marina, Varna

28034

Hospital Universitario Ramón y Cajal, Madrid

49005

Municipal Institution Dnipropetrovsk Regional Clinical Hospital named after I.I. Mechnikov, Dnipropetrovsk

570 10

General Hospital of Thessaloniki, Thessaloniki

15-879

Centrum Zdrowia Stołeczna 7, Bialystok

013686

Spitalul Universitar de Urgenta Elias, Bucharest

Sponsors

Lead Sponsor

AB Science
All Listed Sponsors
lead

AB Science

INDUSTRY